Guardant Health

GH

Market cap $14.6B

Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary unaudited financial results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Total revenue of approximately $280 million, an increase of 39% Reported approximately 79,000 oncology tests, an increase of 38% Report.

Guardant Health stock was near a buy point of 112.43 on Thursday.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and their families through TRICARE, the U.S. military's health insurance coverage, with no copay for average-risk individuals ages 45 and older. Shield is the first and only blood test approved by the FDA as a primary screening option for CRC, offering U.S. military.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Health's management is scheduled to present and participate in a Q&A session on Monday, January 12, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the “Investors” section.

UPPER NYACK, N.Y.--(BUSINESS WIRE)--Colorectal Cancer Detection Is Primary Goal of Global Healthy Living Foundation and Guardant Health.

Every once in a while, a secular trend is so obvious that everyone can see it, and that is the case with AI. Drones are another important secular trend that we believe will benefit many areas of the economy. Robots used to be the province of science fiction movies, but today they are an integral and rapidly expanding area of the economy.

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health (Nasdaq: GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care option, today announced a strategic collaboration to increase access to cancer clinical trials in the United States. The collaboration combines Guardant Health's suite of cutting-edge precision oncology diagnostics with Trial Library's AI-powered matching and patient navigation platform. Together, the comp.

PALO ALTO, Calif. & ROME--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking.

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025. Oral presentations will highlight results generated with Guardant Reveal, the company's tissue-free test for detecting minimal residual disease (MRD.